Dr. Abraham Avigdor is the Director of the Institute of Hematology, Division of Hematology and Bone Marrow Transplantation, Sheba Medical center; Senior Lecturer at the Sackler School of Medicine, TAU. He is a recipient of a several honors: Prize for excellence in medical studies, The Knesset, Israeli Parliament; The Ministry prize for excellent physician, Sheba Medical Center, The Health Ministry of Israel; Basic science award, The European Group for Blood and Marrow Transplantation (EBMT). The Institute of Hematology was established in 1953 and is the largest of its kind in Israel. It offers a comprehensive diagnostic and therapeutic approach to hematological disorders, particularly hematological malignancies Patients’ hematological disorders are evaluated quickly by an array of diagnostic procedures ranging from the basic to the most sophisticated including Cytogenetics, Fluorescence in Situ Hybridization (FISH), Flow Cytometry and DNA analysis by PCR techniques. These procedures allow an accurate diagnosis of the hematological malignancies and provide tools for monitoring response and minimal residual disease, mainstays of modern Cancer therapy. The physical proximity and daily interaction between our treating physicians and laboratory staff assures timely and relevant laboratory evaluation.
- Director of the Institute of Hematology, Division of Hematology and Bone Marrow Transplantation
- Senior Lecturer at the Sackler School of Medicine, TAU
- Founder and President of the Israeli Lymphoma Working Group
- Member of Hematology Consultation team for the Health Basket
Education and Training
- MD from Ben-Gurion University, School of Medicine
- Internship in Internal Medicine and in Hematology at the Sheba Medical Center
- Post-doctoral fellowship in Human hematopoietic stem cell biology at the Weizmann Institute, Department of Immunology.
- Internal Medicine
1. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
2. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
3. All publications